https://www.selleckchem.com/products/NXY-059.html
5% (95% CI 44-47), 46.0% (42-5, 38% (35-41) and 37% (35-41), respectively; death was 19.2% (19-21), 15.3% (12.7-18.4), 29.2% (27-32) and 28.6% (27-31); and SICH was 3.6% (3-4), 4.4% (3.0-6.4), 5.8% (4.7-7.1) and not available. Thrombectomy in routine clinical use registered in the SITS-ISTR showed safety and outcomes comparable to RCTs, and better functional outcomes and lower mortality than previous national registry studies. Thrombectomy in routine clinical use registered in the SITS-ISTR showed safety and outcomes comparable to RCT
Like
Comment
Share
